Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
    • Neurovision
    • Immune cell calender 25
    • Sherlock-MS-Blog
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
English (UK)
Deutsch
English (UK)

Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more

MS Treatments

Jahr

Publikationsjahr
2022

Autoren

Autorenliste der Publikation
Constantinescu V, Akgün K, Ziemssen T.

Verlag

Publisher-Information
Expert Opin Drug Metab Toxicol 2022;18(10):675-693.

Link

Zur Publikation (externer Server)
https://doi.org/10.1080/17425255.2022.2138330

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
Treatments2022

  • Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

    NIL
    Jahr
    2025

  • Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

    MS Treatments
    Jahr
    2025

  • Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

    MS Treatments
    Jahr
    2025

  • A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

    MS Treatments
    Jahr
    2025

  • Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

    MASC
    Jahr
    2025
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more
Impressum & Datenschutz

© 2025
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden